Reproducibility of Dual Beam Doppler Fourier-domain Optical Coherence Tomography in Healthy Subjects

Short- and Long-term Reproducibility of Dual Beam Doppler Fourier-domain Optical Coherence Tomography Measurements in Healthy Subjects - a Pilot Study

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03821467

Enrollment

Registered

2019-01-29

Start date

2018-11-19

Completion date

2025-12-12

Last updated

2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Blood Flow

Keywords

doppler optical coherence tomography, dynamic vessel analyzer

Brief summary

Dual beam Doppler Fourier-domain Optical coherence tomography (DOCT) is a noninvasive technique to quantify total retinal blood flow. To enable further development of this technique it is essential to assess short- and long-term reproducibility of DOCT blood flow measurements.

Detailed description

In the present study, total retinal blood flow will be measured with DOCT at multiple time points to gain information of short- and long-term reproducibility. In addition, provocation with flickering light will be performed, which is known to lead to vasodilatation and an increase in retinal blood flow in healthy subjects. Vessel diameters will also be measured using the Dynamic Vessel Analyzer (DVA).

Interventions

DEVICEDual beam Doppler Fourier-domain OCT (DOCT)

Retinal blood flow will be assessed using DOCT.

DEVICEDynamic Vessel Analyzer (DVA)

Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

DEVICEOptical coherence tomography (OCT)

Retinal morphology will be imaged using OCT.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Men and women aged between 18 and 35 years * Non-smokers * Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant * Normal ophthalmic findings, ametropy \< 3 Dpt.

Exclusion criteria

* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * Treatment in the previous 3 weeks with any drug (except contraceptives) * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Blood donation during the previous 3 weeks * Pregnancy, planned pregnancy or lactating * History or family history of epilepsia

Design outcomes

Primary

Measure	Time frame	Description
Retinal blood-flow variation over time	14 +/- 3 days	as measured using DOCT

Secondary

Measure	Time frame	Description
Flicker induced blood flow alterations	14 +/- 3 days	as measured using DOCT
Flicker induced vasodilatation and hyperemia	14 +/- 3 days	as measured using DOCT and DVA

Countries

Austria

Contacts

Primary ContactDoreen Schmidl, MD, PhD

klin-pharmakologie@meduniwien.ac.at0043140400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026